Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MLNT

Melinta Therapeutics (MLNT) Stock Price, News & Analysis

Melinta Therapeutics logo

About Melinta Therapeutics Stock (NASDAQ:MLNT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.35
$0.50
52-Week Range
N/A
Volume
N/A
Average Volume
713,628 shs
Market Capitalization
$6.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MLNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLNT Stock News Headlines

Something very strange is happening...
What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone noticed when the U.S. Senate granted sweeping powers to a Harvard economist who has some dangerous ideas about the U.S. dollar. Now, he's issued a blueprint for what a coming "Mar-a-Lago Accord" could look like. One analyst who predicted the 2008 crisis says this plan could see the dollar fall in value by 40% in months and become a national nightmare.
SWTX SpringWorks Therapeutics, Inc.
See More Headlines

MLNT Stock Analysis - Frequently Asked Questions

Melinta Therapeutics Inc (NASDAQ:MLNT) announced its earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) earnings per share for the quarter, missing analysts' consensus estimates of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to analysts' expectations of $15.51 million. Melinta Therapeutics had a negative net margin of 393.39% and a negative trailing twelve-month return on equity of 101.29%.

Shares of Melinta Therapeutics reverse split before market open on Friday, February 22nd 2019.The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
11/12/2019
Today
7/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MLNT
Fax
N/A
Employees
290
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$157.19 million
Net Margins
-393.39%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$96.43 million
Price / Cash Flow
N/A
Book Value
$16.96 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$6.88 million
Optionable
Optionable
Beta
4.16
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:MLNT) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners